CD BioGlyco has established a first-class Glycoengineering Platform. We provide clients with efficient antibody remodeling services with G0, G1, G2, or G2S2 glycoforms.
The conserved asparagine (Asn) at position 297 is glycosylated in the CH2 constant domain of the crystallizable fragment (Fc) region of immunoglobulin G (IgG). N-Glycans are important players in Fc effector function and their composition and structure affect effector function by causing conformational changes in the Fc domain. Therefore, Fc glycan remodeling by glycoengineering is a promising strategy for developing therapeutic antibodies with desired function and efficacy.
Cell glycoengineering is the modification of Fc glycans of antibodies by modifying important mediators in the glycan biosynthesis pathway. Currently, there are 3 commonly used methods: 1) Selection of host cell types, environmental factors, and cell culture conditions to produce glycoproteins of desired glycoforms; 2) Modification of host biosynthetic pathways by enzyme inhibitors to obtain target antibodies; 3) Genetically modification of host glycan biosynthetic pathways to obtain glycoproteins.
Chemoenzymatic glycoengineering provides a new approach to remodeling heterogeneous N-glycans into homogeneous Fc glycoform. This method deglycosylates the antibody Fc glycans by specific endoglycosidases to leave the innermost layer of N-acetylglucosamine (GlcNAc). The glycosynthase then catalyzes the reaction of the oxazoline of the target glycan with GlcNAc to generate the homologous Fc glycan.
ADC is a powerful agent for delivering toxins to target cells. Fc glycans are conserved in all IgGs. Therefore, Fc glycan remodeling is designed for site-specific antibody conjugation to obtain structurally well-defined homogeneous ADC. Glycan heterogeneity can be removed by trimming or extending glycan residues to generate homogeneous ADCs.
CD BioGlyco has developed advanced strategies for Antibody Glycoengineering. We provide clients with efficient antibody remodeling services by chemoenzymatic glycoengineering technology. We efficiently remodel specific human IgG (IgG1, IgG2, and IgG4) glycans at the subunit level using predefined and homogenous G0, G1, G2, or G2S2 glycoforms. Our method trims all Fc glycoforms into core GlcNAc by using specific endoglycosidase enzymes. Glycosynthase catalyzes the transglycosylation reaction between exposed core GlcNAc and oxazoline-reactive G0, G1, G2, or G2S2 glycan.
CD BioGlyco has been committed to glycoengineering research for many years. We have developed fast and efficient antibody remodeling strategies. If you are interested in our antibody remodeling services, please contact us for more information.
Reference:
